company background image
CCCC

C4 Therapeutics NasdaqGS:CCCC Stock Report

Last Price

US$8.57

Market Cap

US$419.6m

7D

9.0%

1Y

-75.1%

Updated

01 Dec, 2022

Data

Company Financials +
CCCC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CCCC Stock Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.

C4 Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for C4 Therapeutics
Historical stock prices
Current Share PriceUS$8.57
52 Week HighUS$38.05
52 Week LowUS$4.84
Beta1.97
1 Month Change-10.92%
3 Month Change-15.48%
1 Year Change-75.08%
3 Year Changen/a
5 Year Changen/a
Change since IPO-66.38%

Recent News & Updates

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

Recent updates

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10
Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%

Jun 02
Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%

Read This Before Selling C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares

Mar 15
Read This Before Selling C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares

What You Need To Know About C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Investor Composition

Feb 08
What You Need To Know About C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Investor Composition

Shareholder Returns

CCCCUS BiotechsUS Market
7D9.0%2.3%1.5%
1Y-75.1%-10.2%-14.8%

Return vs Industry: CCCC underperformed the US Biotechs industry which returned -15.2% over the past year.

Return vs Market: CCCC underperformed the US Market which returned -18.9% over the past year.

Price Volatility

Is CCCC's price volatile compared to industry and market?
CCCC volatility
CCCC Average Weekly Movement12.2%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: CCCC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CCCC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015121Andrew Hirschhttps://www.c4therapeutics.com

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers.

C4 Therapeutics, Inc. Fundamentals Summary

How do C4 Therapeutics's earnings and revenue compare to its market cap?
CCCC fundamental statistics
Market CapUS$419.56m
Earnings (TTM)-US$106.65m
Revenue (TTM)US$48.32m

8.7x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CCCC income statement (TTM)
RevenueUS$48.32m
Cost of RevenueUS$87.14m
Gross Profit-US$38.82m
Other ExpensesUS$67.83m
Earnings-US$106.65m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.18
Gross Margin-80.34%
Net Profit Margin-220.71%
Debt/Equity Ratio3.6%

How did CCCC perform over the long term?

See historical performance and comparison